ANDA 211374, held by Amneal. Mycophenolate Mofetil Hydrochloride.
As of Nov 16, 2026, ANDA 211374 (Mycophenolate Mofetil Hydrochloride), held by Amneal, was first approved by FDA on Mar 5, 2021, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 5, 2021 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mycophenolate Mofetil Hydrochloride500MG/VIAL · injectable;injection | Mycophenolate Mofetil Hydrochloride | Discontinued |
| Jul 29, 2026 | Supplement 11REMS | Approved | None posted |
| Aug 13, 2024 | Supplement 8REMS | Approved | None posted |
| Dec 23, 2022 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 23, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 11, 2021 | Supplement 2REMS | Approved | None posted |
| Apr 21, 2021 | Supplement 1REMS | Approved | None posted |
| Mar 5, 2021 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters